Loading stock data…
Loading stock data…
US$5.56
Get one email when VRCA crosses your level. Checked every 15 minutes during market hours.
▼ -0.10 (-1.77%)down today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
41.1
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
-0.06
Bearish momentumMACD below its signal line (-0.00).
50-day average
6.25
Price belowShort-term trend reference.
200-day average
6.04
Price belowLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and commercializing medications for the treatment of skin diseases in the United States. The company's primary product is YCANTH (VP-102), a drug-device combination featuring a topical cantharidin solution with a precision applicator designed for treating molluscum contagiosum and common warts in both adult and pediatric patients. The product has received regulatory approval in Japan and is advancing through phase III …
www.verrica.com3 strong buy · 7 buy · 2 hold · 0 sell · 0 strong sell (12 analysts, 2026-07-01)
3 strong buy · 7 buy · 2 hold · 0 sell · 0 strong sell (12 analysts, 2026-06-01)
3 strong buy · 6 buy · 2 hold · 0 sell · 0 strong sell (11 analysts, 2026-05-01)
3 strong buy · 6 buy · 2 hold · 0 sell · 0 strong sell (11 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-06-25 | -0.14 | -0.16 | ✗ Miss |
| 2026-03-11 | -0.64 | -0.51 | ✓ Beat |
| 2025-11-14 | -0.06 | -0.03 | ✓ Beat |
| 2025-08-12 | -0.83 | 0.25 | ✓ Beat |
| 2025-05-13 | -1.36 | -1 | ✓ Beat |
| 2025-03-11 | -2.42 | -2.01 | ✓ Beat |
| 2024-11-04 | -3.87 | -4.9 | ✗ Miss |
Companies in the same industry, via Finnhub